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Abstract
Background: Recently, we have shown that intraplaque mast cell numbers are associated with atherosclerotic plaque
vulnerability and with future cardiovascular events, which renders inhibition of mast cell activation of interest for future
therapeutic interventions. However, the endogenous triggers that activate mast cells during the progression and
destabilization of atherosclerotic lesions remain unidentified. Mast cells can be activated by immunoglobulins and in the
present study, we aimed to establish whether specific immunoglobulins in plasma of patients scheduled for carotid
endarterectomy were related to (activated) intraplaque mast cell numbers and plasma tryptase levels. In addition, the levels
were related to other vulnerable plaque characteristics and baseline clinical data.
Methods and Results: OxLDL-IgG, total IgG and total IgE levels were measured in 135 patients who underwent carotid
endarterectomy. No associations were observed between the tested plasma immunoglobulin levels and total mast cell
numbers in atherosclerotic plaques. Furthermore, no associations were found between IgG levels and the following plaque
characteristics: lipid core size, degree of calcification, number of macrophages or smooth muscle cells, amount of collagen
and number of microvessels. Interestingly, statin use was negatively associated with plasma IgE and oxLDL-IgG levels.
Conclusions: In patients suffering from carotid artery disease, total IgE, total IgG and oxLDL-IgG levels do not associate with
plaque mast cell numbers or other vulnerable plaque histopathological characteristics. This study thus does not provide
evidence that the immunoglobulins tested in our cohort play a role in intraplaque mast cell activation or grade of
atherosclerosis.
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Introduction
The incidence of atherosclerotic disease is increasing by the
aging population and the life style in the Western world. The mast
cell, a prominent inflammatory cell type and a major effector cell
in allergy and asthma, has been shown to accumulate both in the
rupture-prone shoulder region of human atheromas (1,2) and in
the perivascular tissue during atherosclerotic lesion progression (3).
Recently, we have shown that intraplaque mast cell numbers are
associated with plaque vulnerability and interestingly, with future
cardiovascular events (4). In that study, mast cells numbers
associated with vulnerable plaque characteristics such as lipid core
size, intraplaque haemorrhage, microvessel density and inflam-
matory cell accumulation, suggesting that mast cells actively
contribute to atherosclerotic plaque progression and destabiliza-
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tion. Inhibition of mast cell activation may therefore be of interest
for future therapeutic interventions. However, the mechanism of
mast cell activation during the development of atherosclerosis
remains up to date unresolved. Previously, we and others have
established that mast cells in the vessel wall can be activated by for
example neuropeptides (5), complement factors (6) and lipid
mediators (7) in animal models of atherosclerosis. Furthermore,
the mast cell expresses the high-affinity IgE receptor (FceR1) and
the IgG receptor (FccR) (8,9). Mast cells can be activated via IgE
mediated crosslinking of the FceR, after which mast cells release
granules into the surrounding area. IgE levels have been shown to
be elevated in patients with unstable angina pectoris (10) and
intriguingly, also higher in dyslipidemic men as compared to
control subjects (11). Furthermore, Lappalainen et al demonstrat-
ed that specific oxLDL-IgG immune complexes were able to
induce mast cell activation (12). Circulating specific IgE and IgG
antibodies or lipid-immunoglobulin immune complexes, which
exert their effects through the FceR and FccRs, are known to play
a role in several immune responses (9) and may thus also be
involved in mast cell activation within the atherosclerotic plaque,
thereby affecting plaque stability. Based on these observations, we
hypothesize that circulating immunoglobulins may be involved in
or be reflective of mast cell activation and thereby accelerate the
destabilization of the atherosclerotic plaque. This study was
designed to assess the presence of associations between immuno-
globulin expression and mast cell numbers in plaques from
patients with carotid stenosis. Hence, we assessed total and ox-
LDL specific IgG and total IgE plasma levels and related their
numbers to several mast cell parameters and established vulner-
able plaque characteristics. In additions, immunoglobulin levels
were related to clinical characteristics.
Materials and Methods
Study Population and Design
A total of 135 patients of the Athero-Express were included in
this study. The Athero-express biobank involves patients that
underwent carotid endarterectomy (CEA) in two Dutch teaching
hospitals in Utrecht and Nieuwegein the Netherlands (13). The
criteria to perform carotid endarterectomy were based on the
recommendations by the Asymptomatic Carotid Atherosclerosis
Study (ACAS study) for asymptomatic patients and the North
American Symptomatic Carotid Endarterectomy Trial and the
European Carotid Surgery Trial (NASCET study) for symptom-
atic patients (14–18). Patients were operated between March 2002
and August 2008 of which intraplaque mast cell numbers were
available (4). In that study, patients were selected who remained
healthy and patients who suffered from an event during follow-up
in a 2:1 ratio. Of 135 patients blood plasma samples were
available. Total mast cell numbers and baseline characteristics did
not differ between the patients of which plasma was and was not
available. The local medical ethical boards of both participating
hospitals approved this study. The participating patients signed a
written informed consent prior to inclusion. The patient’s baseline
characteristics and medical history were obtained via question-
naires and the patient medical records.
Materials
The carotid plaques used in this study were processed as
described previously (13). In short, after surgical dissection the
plaque was cut into segments of 5 mm. The segment with the
largest plaque area was fixed in formalin and embedded in
paraffin for histology. The two adjacent sections were frozen in
liquid nitrogen and used for protein isolation. In addition, blood
was drawn prior to CEA procedure and plasma was stored at 2
80uC.
Quantification of Immunoglobulin and MC Tryptase
Levels in Patient Plasma
Plasma total IgE and IgG levels were measured using a human
IgG and IgE ELISA according to manufacturer’s protocol (Bethyl
Laboratories, Montgomery, TX). Plasma IgG-oxLDL levels were
measured by coating cupper oxidized human LDL in PBS
(pH = 9,0) on MaxiSorp 96-well plates (Nunc, Roskilde, Denmark)
overnight at 4uC. Diluted Samples and standards (Biomedica,
Wien) were added and incubated for 2 hours at 37uC.
Supernatants were discarded and plates were washed thoroughly.
Anti-human IgG-HRP (Bethyl Laboratories, Montgomery, TX)
was added as detection antibody for 1 hour at 37uC. Bound
oxLDL-IgG was visualized by using 2,29-azinobis 3-ethylbenzthia-
zoline-6-sulfonic acid (ABTS, Sigma). Colour was measured at an
optical density of 415 nm using a conventional ELISA reader.
Between each ELISA step plates were washed with PBS
containing 0.05% Tween20.
MC tryptase levels were determined in plasma samples using an
ImmunoCAPH 250 tryptase assay (Phadia AB, Uppsala, Sweden).
Immunohistochemistry
Sections were stained for mast cell tryptase (mast cells), CD68
(macrophages), smooth muscle cells (alpha actin), and CD34
(endothelial cells) as previously described (4). Total mast cell
numbers were determined by counting all (degranulating) mast
cells present in a plaque cross-section at640 magnification (4). A
degranulating mast cell was defined by a group of mast cell
tryptase positive extracellular granules in close proximity of each
other or in close proximity of a mast cell. The total plaque area
(mm2) was measured using the analySIS 2.8 software (Olympus
Soft Imaging Solutions GmbH, Mu¨nster, Germany) to determine
the distribution density of mast cells expressed as numbers of mast
cells/mm2. Image-analyzing software was used to determine
positive macrophage and smooth muscle cell staining expressed
as a percentage of covered plaque area (13). Microvessels were
counted in three hot-spots and were expressed as average
microvessel density per hotspots (19). Collagen content (picrosirius
red) was scored semi-quantitatively. The size of the extracellular
lipid core (atheroma) was assessed by the H&E and picrosirius red
stain (13).
Statistics and Data Analysis
IBM SPSS statistics version 20 was used for all analyses (IBM
corporation, Armonk, NY, USA). Immunoglobulin levels are not
normally distributed; non-parametrical testing was used to
determine differences. The Mann-Whitney U test was used to
study immunoglobulin levels as a continuous variable for all risk
factors. The Spearman correlation coefficient was calculated to
assess associations between immunoglobulin levels and all
continuous variables in this study. Differences were considered
significant with a p-value of below 0.05.
Results
Baseline Patient Characteristics
Total IgE, total IgG and oxLDL-IgG plasma levels were
measured in a total of 135 patients that underwent carotid
endarterectomy. Baseline clinical characteristics of the 135
patients are provided in Table 1. The studied patient population
with a mean age of 67 and a male prevalence (71%) reflects a
relatively typical population of patients with vascular occlusive
Plasma Igs Do Not Associate with Plaque Mast Cells
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e88984
diseases. The majority of patients was symptomatic (74%) as
illustrated by the incidence of amaurosis fugax, a TIA or a stroke,
was hypertensive (86%) and used statins (69%).
Plasma Immunoglobulin Levels and Mast Cell Parameters
A correlation with borderline significance was found between
total IgE and oxLDL-IgG (r = 0.169, p = 0.051). Total IgG did not
Table 1. Baseline characteristics of patients in relation to immunoglobulin plasma levels.
Total IgG p-value oxLDL-IgG p-value Total IgE p-value
Age, mean years (sd) 67 (9) r =20.082 0.347 r = 0.031 0.724 r = 0.097 0.265
BMI, mean kg/m2 (sd) 27 (4) r =20.115 0.19 r = 0.001 0.995 r =20.126 0.15
Gender
Male 96/135 (71%) 16.8 [11.7–23.5] 0.694 336 [239–499] 0.074 131.1 [57.5–317.4] 0.169
Female 39/135 (29%) 17.2 [12.6–23.1] 282 [233–358] 76.7 [31.4–293.4]
Current smoker
Yes 55/134 (41%) 16.6 [10.3–23.3] 0.635 303 [252–481] 0.427 173.4 [65.5–449.8] 0.032
No 79/134 (59%) 17.1 [12.3–23.2] 306 [219–502] 91.5 [41.5–203.0]
Diabetes mellitus
Yes 25/135 (19%) 15.4 [12.1–22.9] 0.63 288 [241–391] 0.554 79.8 [41.9–288.5] 0.329
No 110/135 (81%) 17.0 [12.3–23.7] 320 [238–489] 125.0 [57.3–312.1]
Statin Use
Yes 93/135 (69%) 17.1 [12.3–22.8] 0.72 288 [224–406] 0.004 97.5 [43.1–276.8] 0.012
No 42/135 (31%) 16.8 [23.3–25.0] 399 [282–584] 157.3 [75.2–545.4]
Hypertension
Yes 116/135 (86%) 17.2 [12.5–23.2] 0.633 302 [233–480] 0.207 113.0 [49.1–304.8] 0.265
No 19/135 (14%) 15.0 [10.4–26.0] 341 [260–537] 183.3 [68.8–594.0]
Hypersensitive
Yes 27/132 (20%) 17.1 [12.6–22.2] 0.906 305 [233–412] 0.539 148.1 [44.6–449.8] 0.401
No 105/132 (80%) 16.6 [11.6–23.9] 303 [237–489] 115.6 [50.5–304.7]
History VI
Yes 54/135 (40%) 18.5 [11.9–23.5] 0.39 297 [216–483] 0.391 86.2 [47.7–274.4] 0.239
No 81/135 (60%) 15.4 [11.9–23.5] 306 [254–484] 135.4 [54.2–358.9]
History MI
Yes 30/134 (22%) 19.0 [12.7–22.7] 0.673 321 [222–428] 0.62 85.6 [51.7–282.9] 0.601
No 104/134 (78%) 16.5 [12.2–23.5] 304 [239–508] 129.7 [49.1–310.8]
Clinical presentation
Asymptomatic 35/135 (26%) 15.8 [12.3–23.2] 0.419* 314 [239–505] 0.377* 113.0 [47.0–304.9] 0.431*
Symptomatic 100/135 (74%) 18.1 [12.1–24.1] 293 [224–399] 144.3 [68.8–356.7]
Amaurosis fugax 22/135 (16%) 16.6 [12.5–24.9] 296 [240–424] 120.9 [46.3–327.8]
TIA 51/135 (38%) 16.2 [11.5–23.2] 300 [223–512] 106.3 [32.9–281.6]
Stroke 27/135 (20%) 15.4 [12.3–22.7] 352 [257–515] 135.4 [66.6–319.9]
Data are presented as No. (%) and median [IQR] unless otherwise indicated; r = Spearman’s rank correlation coefficient; sd = standard deviation; IQR = interquartile range;
BMI = body mass index; TIA = transient ischemic attack; *p-value represents statistical analysis for asymptomatic patients versus symptomatic patients (composed of
amaurosis fugax, TIA an stroke).
doi:10.1371/journal.pone.0088984.t001
Table 2. Immunoglobulin plasma levels with respect to mast cell parameters.
Total IgG p-value oxLDL-IgG p-value Total IgE p-value
Total mast cells r =20.038 0.664 r = 0.137 0.114 r =20.038 0.664
Mast cells/mm2 r =20.104 0.23 r = 0.115 0.186 r =20.014 0.872
Degranulating mast cells/mm2 r =20.074 0.519 r = 0.008 0.946 r =20.076 0.506
Plasma tryptase r =20.076 0.378 r = 0.040 0.643 r = 0.064 0.457
Data are presented as Spearman’s rank correlation coefficient (r).
doi:10.1371/journal.pone.0088984.t002
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correlate with either total IgE or oxLDL-IgG. No association was
found between total IgE, total IgG and oxLDL-IgG plasma levels
and total mast cell numbers or total degranulating mast cells
(Table 2). In addition we did not observe any association between
the three immunoglobulins and tryptase plasma levels.
Plasma Immunoglobulin Levels and Vulnerable Plaque
Characteristics
As depicted in Figure 1, no consistent associations were found
between immunoglobulin levels and measures of vulnerable
plaque phenotype. There was no association between immuno-
globulin levels and any of the following plaque characteristics: fat
deposition, collagen, smooth muscle cells, macrophages and
microvessel density.
Plasma Immunoglobulin Levels and Clinically Relevant
Characteristics
Table 1 provides an overview of the associations between the
three immunoglobulin expression levels and relevant clinical
characteristics. A negative association was observed between statin
use and total IgE (97.5 [43.1–276.8] vs. 157.3 [75.2–545.4] ng/
mL, p = 0.012) and oxLDL-IgG (288 [224–406] vs. 399 [282–584]
mU/mL, p = 0.004). Higher total IgE levels were observed in
smokers compared to non-smokers (91.8 [62.3–145.0] vs. 76.7
[47.1–111.2] ng/mL, p = 0.002). Clinical presentation was not
associated immunoglobulin levels: no differences were observed in
expression levels for any of the immunoglobulins between
asymptomatic patients (n = 35) and symptomatic (n = 100) pa-
tients. Furthermore, we did not detect any differences in any of the
circulating immunoglobulin levels between the subgroups of
symptomatic patients (i.e. patients suffering from amaurosis fugax,
TIA or stroke). Additionally, no association was found between
immunoglobulin levels and the delay between surgery and
presentation of symptoms.
Discussion
Progression of an atherosclerotic plaque is often characterized
by measures of plaque vulnerability. A vulnerable plaque is prone
to rupture resulting in severe cardiovascular complications.
Experimental studies have shown that mast cell activation results
in progression and destabilization of the atherosclerotic plaque
(20,21). In addition, in human plaques, mast cells correlated with
vulnerable plaque characteristics and appeared associated with
future combined cardiovascular events (4). It has been suggested
that activated mast cells induce intraplaque neoangiogenesis
thereby making the plaque more susceptible for rupture. For
therapeutic intervention, identification of the endogenous mast cell
activators during the progression and destabilization is of great
value. In allergy and asthma, IgE is the main trigger for mast cell
degranulation via crosslinking of the FceR, while specific IgG
immune complexes can exert mast cell activation resulting in
cytokine release via binding to various Fcc receptors. Previous
studies have demonstrated that plasma IgE levels may be linked to
the presence of cardiovascular diseases (11) and mice lacking the
FceR displayed reduced atherogenesis (22). Furthermore, oxLDL
specific IgG molecules that can form immune complexes with
oxLDL have been detected in human and rabbit atherosclerotic
plaques (23) and these immune complexes were able to induce
TNFa and IL-8 release from human mast cells (12). Taken
together, these data suggest that IgE and specific IgGs may be
important mast cell activators in cardiovascular disease.
It is however still unknown whether circulating immonuglobu-
lins are capable of activating mast cells in human atherosclerotic
plaques. Here we show that circulating IgG, IgE and oxLDL-IgG
are not associated with mast cell determinants in a patient cohort
with severe carotid stenosis that underwent an endarterectomy. No
association was observed between any of the three immunoglob-
ulins measured in this study and total plaque mast cell numbers or
mast cell tryptase plasma levels. In addition, we did not observe
Figure 1. No association were found between IgE (left graphs),
IgG (middle graphs) and oxLDL-IgG (right graphs) levels and
any of the plaque characteristics: fat deposition, collagen,
smooth muscle cells, macrophages and microvessel density.
doi:10.1371/journal.pone.0088984.g001
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any correlation with intraplaque degranulating mast cell numbers.
Our results do not provide supportive evidence that increased
immunoglobulin levels induce activation of mast cells in advanced
human atherosclerotic plaques.
Previously, IgE was shown an independent marker for
cardiovascular disease in men (24). Therefore we explored the
possibility of an association between the three immunoglobulins
had any future adverse events in patients with established
cardiovascular disease. We did not find any association between
immunoglobulin levels and future cardiovascular events, however,
we were underpowered for analysing risk prediction for the
immunoglobulins in our cohort. Nevertheless, no association was
found with histological markers of plaque vulnerability, one of the
most important determinants for future cardiovascular complica-
tions.
Serum oxLDL specific IgG antibodies have previously been
linked to the presence and destabilization of the atherosclerotic
plaque (25). As mentioned above, specific IgGs have been
observed within the atherosclerotic plaque. In the current study,
we did not detect any correlation between plasma oxLDL-IgG
levels and mast cell activation or plaque phenotype. However,
systemic oxLDL-IgG levels may not reflect the local oxLDL-IgG
immune complexes that may actually activate the mast cell within
the atherosclerotic plaque. Histological analysis of immune
complexes, and with that also local IgE content, and colocalization
with mast cells within the plaque may provide more information
on the mechanisms of mast cell activation in atherosclerosis.
Interestingly, lower IgE and oxLDL-IgG levels were observed in
patients that used statins. When we differentiated between the
patients on statins and the patients not on statins it does not affect
the outcome of the associations observed between immunoglob-
ulin levels and mast cell parameters or plaque vulnerability (data
not shown). The inhibitory effects of statin use on oxLDL-IgG
antibody levels have been previously described (25), however
reduced levels of IgE after statin treatment has to our knowledge
not been reported before in patients with atherosclerosis. These
data thus identify a novel effect of statin treatment, in addition to
lipid-lowering, possibly by affecting antibody production of B cells.
The results of our study may be limited by the relative small
number of patients. We have previously established that plasma
tryptase levels of these patients correlate with plaque mast cell
number and activation status, thus being reflective of mast cell
activation. However, using these patients we were unable to detect
a relation between any of the measured circulating immunoglob-
ulin levels and intraplaque mast cell numbers or its activation,
which may be improved by using a larger patient cohort. In
addition, we measured plasma immunoglobulin levels at a single
time-point that is at time of carotid endarterectomy, which is most
reflective of the mast cell status within the plaque at that time
point. Measuring plasma immunoglobulin levels at multiple time-
points, for example at follow-up, may provide more information
on the variation in circulating immunoglobulin levels together with
disease progression.
In conclusion, no associations were found for total IgE, total
IgG and oxLDL-IgG and the presence of total mast cell numbers
or the number of degranulating mast cells in atherosclerotic
plaques. Furthermore, the immunoglobulins were not related to
most of the established characteristics of the rupture-prone
atherosclerotic plaques. Taken together, this study does not
provide supportive evidence that the three investigated circulating
immunoglobulins activate mast cells during the progression of
atherosclerotic disease. We can however not exclude that the mast
cells may be activated by other specific immunoglobulins, or that
local factors within the vessel wall are more predominant
determinants of mast cell activation in the atherosclerotic plaque.
Future research on the local environmental specific IgE and IgG
levels within the plaque may thus shed more light on mechanism
of mast cell activation in atherosclerosis.
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